Elisa Greggio Selected Research

Leucine (L-Leucine)

1/2022	Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease.
1/2022	Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease.
1/2022	The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
1/2022	LRRK2 as a target for modulating immune system responses.
1/2022	A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively.
1/2020	Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease.
12/2019	Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
1/2019	The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
12/2018	The role of LRRK2 in cytoskeletal dynamics.
1/2018	The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisa Greggio Research Topics

Disease

51	Parkinson Disease (Parkinson's Disease) 01/2022 - 04/2005
4	Inflammation (Inflammations) 10/2018 - 03/2014
2	Leprosy (Hansen's Disease) 01/2022 - 07/2012
2	Pathologic Processes 01/2022 - 01/2012
2	Parkinsonian Disorders (Parkinsonism) 01/2020 - 03/2009
2	Neuroblastoma 10/2014 - 03/2010
1	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2022
1	Gliosis 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Epilepsy (Aura) 12/2019
1	Partial Epilepsies (Epilepsy, Partial) 10/2016
1	Temporal Lobe Epilepsy 10/2016
1	Neoplasms (Cancer) 07/2014
1	Malignant Fibrous Histiocytoma 01/2014
1	Crohn Disease (Crohn's Disease) 07/2012

Drug/Important Bio-Agent (IBA)

41	Phosphotransferases (Kinase)IBA 01/2022 - 06/2007
36	Leucine (L-Leucine)FDA Link 01/2022 - 06/2007
15	Proteins (Proteins, Gene)FDA Link 08/2022 - 07/2007
9	GTP Phosphohydrolases (GTPases)IBA 01/2022 - 02/2008
7	SynucleinsIBA 01/2021 - 06/2011
4	alpha-SynucleinIBA 07/2021 - 03/2010
4	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 04/2005
2	Leucine-Rich Repeat ProteinsIBA 01/2019 - 01/2017
2	Death-Associated Protein KinasesIBA 07/2014 - 01/2014
1	Polytetrafluoroethylene (Teflon)FDA Link 08/2022
1	Transcription Factors (Transcription Factor)IBA 08/2022
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	CatecholaminesIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 01/2021
1	ClusterinIBA 01/2021
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2021
1	Protein AggregatesIBA 01/2021
1	Tryptophan-tRNA LigaseIBA 01/2020
1	Levodopa (L Dopa)FDA LinkGeneric 01/2020
1	Levetiracetam (Keppra)FDA LinkGeneric 12/2019
1	CeramidesIBA 01/2019
1	EnzymesIBA 01/2019
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2017
1	Guanosine Triphosphate (GTP)IBA 01/2017
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 12/2015
1	LipopolysaccharidesIBA 12/2015
1	p21-Activated KinasesIBA 12/2015
1	Neurotransmitter Agents (Neurotransmitter)IBA 06/2013
1	LipidsIBA 06/2011
1	cysteine sulfinic acidIBA 03/2009
1	Cysteine (L-Cysteine)FDA Link 03/2009
1	Melanins (Melanin)IBA 04/2005
1	Monophenol Monooxygenase (Tyrosinase)IBA 04/2005

Therapy/Procedure

2	Therapeutics 12/2019 - 06/2013